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Deep brain stimulation (DBS)
Nonlinear dynamics Efficacy of deep brain stimulation (DBS) treatment was quantified here by using surface EMG and
acceleration measurements.
 EMG signal features differed between different DBS settings for biceps brachii muscles.
 EMG features pointed to previously defined optimal settings in most of patients.
a b s t r a c t
Objective: Electromyography (EMG) and acceleration (ACC) measurements are potential methods for
quantifying efficacy of deep brain stimulation (DBS) treatment in Parkinson’s disease (PD). The treatment
efficacy depends on the settings of DBS parameters (pulse amplitude, frequency and width). This study
quantified, if EMG and ACC signal features differ between different DBS settings and if DBS effect is
unequal between different muscles.
Methods: EMGs were measured from biceps brachii (BB) and tibialis anterior (TA) muscles of 13 PD
patients. ACCs were measured from wrists. Measurements were performed during seven different set-
tings of DBS and analyzed using methods based on spectral analysis, signal morphology and nonlinear
dynamics.
Results: The results showed significant within-subject differences in the EMG signal kurtosis, correlation
dimension, recurrence rate and EMG–ACC coherence between different DBS settings for BB but not for TA
muscles. Correlations between EMG feature values and clinical rest tremor and rigidity scores were weak
but significant.
Conclusions: Surface EMG features differed between different DBS settings and DBS effect was unequal
between upper and lower limb muscles.
Significance: EMG changes pointed to previously defined optimal settings in most of patients, which
should be quantified even more deeply in the upcoming studies.
 2015 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights
reserved.1. Introduction
Several parts of the brain participate in controlling the posture,
force and movements in humans. These parts include the premotorand primary motor cortex, cerebellum and basal ganglia (Moritani
et al., 2004). In Parkinson’s disease (PD), there is a progressive
degeneration of dopaminergic neurons in the substantia nigra in
the basal ganglia. This leads to abnormalities in the basal ganglia
function and finally to the primary symptoms of PD: resting tre-
mor, rigidity (increased muscle tone) and bradykinesia (slowness
of movements) (Wichmann et al., 2008). PD cannot be cured but
the symptoms can be relieved with medication that aims either
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the brain (Gárdián and Vécsei, 2010). Deep brain stimulation (DBS)
can be used to treat advanced PD, when optimal oral medication
fails to sufficiently control motor symptoms. The most common
target is subthalamic nucleus (STN), although Globus Pallidus
Interna (GPi) stimulation has also been used as treatment option
in advanced PD (Malhado-Chang et al., 2008). DBS delivers high
frequency current to stimulate the STN in the basal ganglia result-
ing in a complex pattern of excitatory and inhibitory effects that
modulate the entire network between basal ganglia, thalamus
and cortex. It is thought that DBS regularizes neuronal patterns
preventing the transmission of pathologic bursting and oscillatory
activity in the brain. This results in improved processing of the sen-
somotor information and alleviation of motor symptoms
(Miocinovic et al., 2013). Often there is a significant reduction in
the daily levodopa dose, when STN is stimulated (Benabid et al.,
2009; Malhado-Chang et al., 2008).
Efficacy of DBS treatment depends significantly on the correct
placement of stimulation electrodes, and on the optimal settings
of stimulation parameters. In constant-voltage mode (which is
the most common mode used), the controllable stimulation para-
meters are the amplitude, frequency and width of the stimulation
pulse. By choosing active electrode contacts and their polarity, the
electrical current can be targeted to correct neural elements
(Volkmann et al., 2006; Montgomery, 2010). In some cases, the
optimization of DBS treatment is not straightforward because the
stimulation parameters are set by subjective evaluation of symp-
toms and the symptoms may respond to DBS with a variable delay
(Levin et al., 2009; Groiss et al., 2009). Rigidity and tremor respond
usually within a few minutes and they require only little co-op-
eration from the patient. The tremor may, however, be influenced
by the emotional state in some patients. Bradykinesia may respond
to DBS in several hours or even days. Therefore, the changes in
bradykinesia may not be observed during the DBS adjustment ses-
sion in all patients (Malhado-Chang et al., 2008; Volkmann et al.,
2006). With a careful adjustment of stimulation parameters also
the unpleasant adverse effects such as dyskinesia, dystonia (invol-
untary muscle contractions), dysarthria (speech problems) and
abnormal eye function (e.g. diplopia), may be eliminated
(Malhado-Chang et al., 2008; Miocinovic et al., 2013).
The DBS parameters have a therapeutic range, inside which the
clinical efficacy is maximal while the current consumption stays
reasonable. It has been observed that an increase in the stimulation
amplitude leads to increase in the distance of the stimulated neural
elements and usually to a reduction in motor symptoms
(Volkmann et al., 2006). On the other hand, amplitude increase
may give rise to unwanted side-effects by stimulating adjacent ele-
ments besides STN (Groiss et al., 2009). Therapeutic amplitudes
range between 1 and 3.5 V, above which the electrical current con-
sumption may rise abruptly (Volkmann et al., 2006). The adjust-
ment of pulse amplitude is usually done in 0.3–0.5 V steps
(Montgomery, 2010). If needed, the pulse width (60–90 ls) can
be increased in order to compensate reduction in the stimulation
amplitude (Malhado-Chang et al., 2008). It is known that low
DBS frequencies (<10 Hz) may increase parkinsonian symptoms
and high frequencies reduce them. The therapeutic pulse frequen-
cies are thought to be above 100 Hz and usually maximal benefit of
DBS is around 130 Hz (Volkmann et al., 2006). However, it has been
noticed that high-frequency DBS (130 Hz) may worsen gait and
speech while low-frequency DBS (60 Hz) may improve them in
some patients (Xie et al., 2012; Montgomery, 2010; Moreau
et al., 2008). System Oscillations theory (Montgomery, 2010) has
been suggested as one explanation for that.
Surface electromyography (EMG) enables the objective
quantification of neuromuscular function. Therefore, it may be use-
ful in quantifying treatment efficacy in PD. Previous EMG-basedstudies have shown that DBS may change the EMG signal charac-
teristics by increasing the dominant tremor frequency in the
EMG spectrum (Blahak et al., 2007; Sturman et al., 2004) and by
reducing the EMG–acceleration coherence during a resting condi-
tion and with backward counting (Sturman et al., 2004, 2007).
DBS may also increase the size of the first agonist burst and the
number of agonist bursts during rapid point-to-point movements
of the elbow and ankle (Vaillancourt et al., 2004, 2006). Rissanen
et al. (2011) have presented previously a principal component
(PC)-based tracking method for quantifying the effects of DBS in
PD by using EMG and kinematic measurements and analysis. The
presented method was capable of detecting differences in the sur-
face EMG and acceleration (ACC) signal features between the DBS
on- and DBS off-states. However, it stays unclear, if muscle activa-
tion and surface EMG are unequal between different settings of the
DBS parameters. If surface EMG was unequal between different
settings of DBS treatment, it could work in helping the optimal
adjustment of DBS treatment. It is also unclear, if surface EMG is
changed similarly in upper and lower extremity muscles during
the adjustment of DBS settings.
This study aims answer to three questions: What happens to
the surface EMG signal characteristics of arms and legs:
 when the stimulation amplitude is increased or decreased with
0.3 V?
 when the stimulation frequency is increased or decreased with
30 Hz?
 when the stimulation pulse width is increased with 30 ls?
In this study, surface EMGs were measured from the biceps brachii
(BB) and tibialis anterior (TA) muscles of 13 PD patients with pre-
viously implanted DBS during seven different settings (varying
stimulation amplitude, frequency or pulse width) of the DBS treat-
ment. The selected DBS settings were supposed to be safe for the
patients and causing minimal side-effects. The measured signals
were analyzed using different EMG signal parameters.2. Methods
2.1. Subjects
Thirteen patients with advanced PD participated in this study
after giving their informed consent. All patients had been treated
with bilateral STN-DBS (Kinetra or Activa PC Neurostimulators,
Medtronic Inc., Minneapolis, MN, USA) for 2–34 months. The
details of patients, clinical scores (total scores of UPDRS III Motor
Examination), STN-DBS details and medications are given in
Table 1. The study was approved by the local human ethics com-
mittee of the Kuopio University Hospital. The EMG measurements
were performed during seven different stimulation settings which
are detailed in Table 2. The setting state S0 refers to the previously
(less than 6 months ago) defined optimal parameter values that
each patient had used for DBS treatment. Because of severe symp-
toms, the patients were on-medication during the measurements.
If the patient suffered from difficult adverse effects with some
stimulation settings, the measurement was canceled and the ana-
lysis was not performed with those settings. One patient could not
be measured with Aþ and one patient with DBS OFF. Four patients
could not be measured with Wþ. The order of setting states Aþ,
A, Fþ, F and Wþ was randomized between patients in the mea-
surements. However, the first setting state was S0 in all patients,
which corresponds to typical adjustment session of previously
implanted DBS. From that state we got the reference values for
clinical scores. The last setting state studied was OFF in all patients,
because the symptoms were quite severe in many patients when
Table 1
Patients, clinical scores, STN-DBS details and medications.




Optimal settings of STN-DBS Medications and levodopa equivalent doses (LEDs) calculated according to
Tomlinson et al. (2010)
1 46 M 21 (36) 5 Right: A0 = 3.5 V, F0 = 130 Hz,
W0 = 60 ls; Left: A0 = 3.7 V,
F0 = 130 Hz, W0 = 60 ls
Levodopa/carbidopa/entacapone 150 mg/37.5 mg/200 mg5, rasagiline
1 mg1 and pramipexole 1.57 mg1 (total LED 1257 mg)
2 59 F 26 ( 37) 34 Right: A0 = 3.4 V, F0 = 130 Hz,
W0 = 60 ls; Left: A0 = 3.2 V,
F0 = 130 Hz, W0 = 60 ls
Levodopa/carbidopa/entacapone 150 mg/37.5 mg/200 mg4,
levodopa/carbidopa/entacapone 125 mg/31.25 mg/200 mg2, carbidopa/
levodopa 50 mg/200 mg1, rotigotine 6 mg/24 h and if needed levodopa/
benserazide 100 mg/25 mg1–2 (total LED 1516–1716 mg)
3 64 M 22 (29) 23 Right: A0 = 3.1 V, F0 = 130 Hz,
W0 = 60 ls; Left: A0 = 3.3 V,
F0 = 130 Hz, W0 = 60 ls
Levodopa/carbidopa/entacapone 75 mg/18.75 mg/200 mg5, rotigotine
10 mg/24 h and if needed levodopa/benserazide 50 mg/12.5 mg (total LED
803–853 mg)
4 58 F 10 (18) 5 Right: A0 = 2.6 V, F0 = 130 Hz,
W0 = 60 ls; Left: A0 = 2.5 V,
F0 = 130 Hz, W0 = 60 ls
Levodopa/carbidopa/entacapone 50 mg/12.5 mg/200 mg1, ropinirole
12 mg1 and rasagiline 1 mg1 (total LED 407 mg)
5 64 M 16 (36) 2 Right: A0 = 2.8 V, F0 = 130 Hz,
W0 = 60 ls; Left: A0 = 3.4 V,
F0 = 130 Hz, W0 = 90 ls
Pramipexole 1.05 mg1 and levodopa/benserazide 100 mg/25 mg2 (total
LED 205 mg)
6 66 M 21 (28) 8 Right: A0 = 2.5 V, F0 = 130 Hz,
W0 = 60 ls; Left: A0 = 2.5 V,
F0 = 130 Hz, W0 = 60 ls
Carbidopa/levodopa 25 mg/100 mg3, pramipexole 2.1 mg1 and rasagiline
1 mg1 (total LED 610 mg)
7 66 M 34 (45) 21 Right: A0 = 2.3 V, F0 = 130 Hz,
W0 = 60 ls; Left: A0 = 3.3 V,
F0 = 130 Hz, W0 = 60 ls
Ropinirole 8 mg1, carpidopa/levodopa 12.5 mg/50 mg3 and selegiline
10 mg1 (total LED 410 mg)
8 38 M 27 (50) 22 Right: A0 = 3.4 V, F0 = 130 Hz,
W0 = 60 ls; Left: A0 = 3.4 V,
F0 = 130 Hz, W0 = 60 ls
Levodopa/carbidopa/entacapone 50 mg/12.5 mg/200 mg2 and pramipexole
2.1 mg1 (total LED 344 mg)
9 71 M 22 (36) 4 Right: A0 = 3.1 V, F0 = 130 Hz,
W0 = 60 ls; Left: A0 = 3.4 V,
F0 = 130 Hz, W0 = 60 ls
Carbidopa/levodopa 25 mg/100 mg5 (total LED 500 mg)
10 47 M 31 (38) 4 Right: A0 = 2.3 V, F0 = 180 Hz,
W0 = 60 ls; Left: A0 = 2.5 V,
F0 = 180 Hz, W0 = 60 ls
Levodopa/carbidopa 100 mg/25 mg3–4, rotigotine 4 mg/24 h and selegiline
10 mg1 (total LED 521–621 mg)
11 58 F 12 (23) 6 Right: A0 = 2.4 V, F0 = 130 Hz,
W0 = 60 ls; Left: A0 = 2.4 V,
F0 = 130 Hz,W0 = 60 ls
Levodopa/carbidopa/entacapone 50 mg/12.5 mg/200 mg6, pramipexole
1.05 mg1, levodopa/carbidopa 200 mg/50 mg1 and rasagiline 1 mg1
(total LED 807 mg)
12 70 M 31 (62) 30 Right: A0 = 2.7 V, F0 = 130 Hz,
W0 = 60 ls; Left: A0 = 3.3 V,
F0 = 130 Hz, W0 = 60 ls
Levodopa/carbidopa/entacapone 50 mg/12.5 mg/200 mg4, levodopa/
benserazide 100 mg/25 mg1 and carbidopa/levodopa 50 mg/200 mg1
(total LED 568 mg)
13 45 M 31 ( 36) 29 Right: A0 = 3.1 V, F0 = 120 Hz,
W0 = 60 ls; Left: A0 = 3.1 V,
F0 = 120 Hz, W0 = 60 ls
Levodopa/carbidopa/entacapone 75 mg/18.75 mg/200 mg10, rasagiline
1 mg1 and ropinirole 2 mg1 (total LED 1140 mg)
a UPDRS III on was evaluated with the optimal DBS settings (S0) at the beginning of measurement session. UPDRS III off was evaluated with DBS off and medication on. For
Patient 2 and Patient 13, UPDRS III off could not be completely estimated because of difficult symptoms. Therefore, the -notion is used.
b DBS months means the number of months after DBS implantation.
Table 2
Settings of DBS.
DBS settings code Pulse amplitude Stimulation frequency Pulse width
S0 A0 F0 W0
A A0 0:3 V F0 W0
Aþ A0þ 0:3 V F0 W0
F A0 F0 30 Hz W0
Fþ A0 F0þ 30 Hz W0
Wþ A0 F0 W0þ 30 ls
OFF OFF OFF OFF
A0, F0 and W0 are the individual previously defined optimal values for each patient.
2292 S.M. Rissanen et al. / Clinical Neurophysiology 126 (2015) 2290–2298the stimulator was switched off and we did not want the patients
to stop the study before trying all setting states.
During each setting state, a DBS-experienced neurologist
evaluated the severity of resting tremor and rigidity in the upper
and lower limbs. The neurologist and the patient were not blind
to the DBS settings. EMG measurement was started five minutes
after the adjustment of parameters and new settings were adjusted
soon after the measurement. In that way, we could minimize the
effects of medication on results while the total time needed for
measurements was minimized. Five minutes was chosen based
on our clinical experience that the response to resting tremorand rigidity appears quite soon (in optimal cases within few min-
utes and usually well below five minutes) while programming DBS
in advanced PD. This finding is supported by the DBS-study of
Moro et al. (2002) that demonstrated clear response to DBS after
five minutes of DBS-reprogramming. Also a study of Airaksinen
et al. (2012) with magnetoencephalography (MEG) showed that
the brain activity of advanced PD patients was changed within five
minutes after switching the DBS on or off. In that study, a negative
correlation of occipital alpha was found with UPDRS motor scores
and rigidity subscores (Airaksinen et al., 2012). Response to motor
fluctuations may appear more slowly, but in this study the tremor
and rigidity were the focus of interest.
In the clinical evaluation, ten patients showed changes in the
severity of tremor or rigidity of arms or legs between different
DBS settings and three other patients did not have any tremor or
rigidity during the measurements. These three patients had
received DBS treatment mainly due to difficult on–off fluctuation
in symptoms.
2.2. Measurements
In this study, isometric contractions of BB and TA muscles were
studied. During the measurement from BB, subjects were asked to
hold their elbows at a 90 angle with their palms up for 20 s.
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their toes up while keeping the heel on the floor for 10 s. During
both tasks, subjects were sitting on a chair and their arms and legs
were not loaded with additional weights. Loading was not used
because the PD-related EMG signal features are most visible in
the unloaded condition (Meigal et al., 2009).
Surface EMGs were measured from both BB and TA muscles by
using disposable Ag/AgCl electrodes (Medicotest, model M-00-S,
Ølstykke, Denmark) in bipolar connection (center-to-center inter-
electrode spacing 3 cm) as by Rissanen et al. (2011). The reference
electrodes were placed 6–7 cm laterally from the recording elec-
trodes. ME6000 -biosignal monitor (Mega Electronics Ltd., Kuopio,
Finland) was used for signal registration with a sampling frequency
of 1000 Hz. The raw EMG signals were analogically band-pass fil-
tered with an anti-aliasing filter (Butterworth, band-pass 8–
500 Hz) and amplified (differential amplifier, CMRR > 130 dB, total
gain 1000, noise <1 lV). The signal analysis was done with a PC
after 14-bit analogue-to-digital conversion. One isometric contrac-
tion of BBs and one isometric contraction of TAs were measured for
each patient during each setting state of DBS parameters.
The accelerations of forearms were measured by using tri-axial
accelerometers (Meac-x, Mega Electronics Ltd., range ±10 g) on the
palmar side of wrists. ACC signals can describe of possible tremor
and other involuntary movements during the isometric muscle
contraction. The accelerations were not measured from the legs.
2.3. Signal analysis
2.3.1. Pre-processing of signals
The middle 18-s long segment of the BB task and the middle 6-s
long segment of the TA task were analyzed by using Matlab (The
MathWorks, Inc.). EMG signals were high-pass filtered (cut-off
10 Hz) with smoothness priors method as by Rissanen et al. (2007).
The DBS artifact (at stimulation frequency Fstim between 100
and 210 Hz) and its harmonics were removed from the EMG sig-
nals of BB in two stages. First, the EMGs were low-pass filtered
with a 9th-order Butterworth filter (cut-off frequency 150 Hz).
Then, the DBS artifacts below 150 Hz were removed by interpolat-
ing the Fourier transform of EMG signal around the stimulation
artifact (between Fstim  2:5 Hz and Fstim þ 2:5 Hz) and taking the
inverse Fourier transform in order to get the filtered signal (see
the method theory by Mewett et al. (2004)). The EMG signals of
TA did not contain DBS artifacts. This is likely because the distance
between the pulse generator and legs is longer than the distance
between the pulse generator and the arms. Therefore, the EMG sig-
nals of TA were not low-pass-filtered before analysis. However, it
was checked that the results would had been the same if the filter-
ing had been done similarly for EMG signals from both muscles.
2.3.2. EMG features
Following PD-characteristic signal parameters were extracted
from the EMG signals of BB and TA:
 sample kurtosis of EMG
 recurrence rate of EMG
 correlation dimension of EMG
 coherence parameter between EMG and ACC (only for arms)
The parameters were calculated from the measurements of both
sides of the body.
The calculation methods of the parameters have been presented
previously by Rissanen et al. (2012) and they can be interpreted as
follows. Sample kurtosis is the fourth centered moment of EMG
sample values, and therefore it measures the impulsiveness of
EMG signal. Sample kurtosis is generally higher in PD patients than
in healthy subjects. Correlation dimension and recurrence rate aremethods of nonlinear dynamics. The parameters are calculated
from embedding vector distances. The embedding vectors are
formed from EMG signal by taking time shifted samples. Correla-
tion dimension quantifies the complexity of EMG signal and it is
usually lower in PD patients than in healthy subjects. Recurrence
rate measures the percentage of recurring structures in the EMG
and it is usually higher in PD patients than in healthy subjects.
Coherence parameter measures similarities in the EMG and ACC
spectra. The power spectral densities of EMG and ACC and their
cross-spectral density were estimated here by using Welch’s aver-
aged periodogram method. The coherence parameter is the area of
the magnitude squared coherence spectrum in the frequency range
[0–50] Hz (Rissanen et al., 2008, 2009).
We examined within-subject differences in the signal para-
meters with respect to previously defined optimal DBS settings
S0 by using paired samples t-test for normally distributed variables
and Wilcoxon signed rank test for other variables. The normality of
parameter distribution was checked with the Lilliefors test.3. Results
3.1. Clinical UPDRS-scores of patients
UPDRS-subscores (III. Motor Examination) of resting tremor and
rigidity were clinically evaluated by a neurologist with each setting
state. In UPDRS, each subscore gets a value between 0 and 4 and
higher scores mean more severe symptoms. The evaluated tremor
and rigidity score differences with respect to state S0 are presented
as a histogram for each DBS setting state in Fig. 1. In the figure, a
negative score difference means reduction and a positive score dif-
ference an increase in symptom severity. The total number of score
differences (i.e. cases) per each setting state was between 18 and
26, because the scores were evaluated for both (right and left side)
arms and legs. Because of severe adverse effects the scores could
not be evaluated for all 13 patients in all setting states.
One can observe in Fig. 1, that the arm tremor scores were the
same or higher with A and F than with the state S0 in all
patients. With the state OFF, they were the same or higher than
with the state S0 in 91% of cases. The rigidity scores of arms were
the same or lower with the state Aþ than with the state S0 in all
cases. With the state OFF, they were the same or higher than with
the state S0 in 95% of cases. The leg tremor and rigidity scores were
the same or higher with the state OFF than with the state S0 in all
patients. The rigidity scores of legs were the same or lower with
the states Aþ and Fþ than with the state S0 in all patients. The
reductions in the scores with respect to increase in the stimulation
amplitude or frequency are in concordance with previous findings
(Volkmann et al., 2006). However, it must be noted that higher
parameter values may cause adverse effects in some patients.3.2. Visual inspection of EMG signals
EMG signals of PD patients were visually inspected. EMG
recordings from the BB of one PD patient (Patient 2) during seven
different settings of DBS are presented in Fig. 2. One can observe
that the EMGs of the patient contain recurring EMG bursts with
the state OFF and with F. Some clustering of motor unit action
potentials can be observed also with Wþ. With other settings
(S0;A;Aþ and Fþ) the EMG signals look similar to the EMG sig-
nals of healthy subjects as presented by Rissanen et al. (2011).
According to clinical evaluation, the arm tremor of the patient
was highest with the state OFF and with F, and with other
settings (S0;A;Aþ; Fþ and Wþ) no tremor was observed.
Upper arm rigidity score was highest with the state OFF, and with
F and Wþ the rigidity score was low. With other settings
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Fig. 1. Histogram of differences in the clinical scores of rest tremor and rigidity with respect to state S0 for 13 PD patients (for each patient there is one right and one left side
value) during each setting state of DBS treatment.
2294 S.M. Rissanen et al. / Clinical Neurophysiology 126 (2015) 2290–2298(S0;A;Aþ and Fþ), no rigidity was observed. In this patient, the
clinical scores are consistent with the visual inspection of EMG sig-
nal morphology. Similar differences between the DBS settings were
observed in the BB EMGs of other patients as well. However, the
differences were not as clear in all patients.
EMG recordings from the TA of one PD patient (Patient 7) are
presented in Fig. 3. One can observe that the EMG signals contain
PD-characteristic spikes or bursts during all settings. However,
during Fþ and Wþ there seems to be fewer spikes than during
other settings. During OFF-state, the spikes are clustered into
recurring bursts with the frequency of 4 Hz. In clinical evaluation,
the tremor score of legs was highest with the state OFF and with
F, and no tremor was observed during Fþ and Wþ. The rigidityscore was lowest during Aþ and Wþ, and equal during
S0;A; F; Fþ and OFF. According to the visual inspection of sig-
nals, during states Fþ and Wþ the EMG signals look closest to
the signals of healthy subjects although PD-characteristic spikes
are present also during those states. According to the clinical eval-
uation, the tremor and rigidity scores would be lowest during
Wþ; Fþ and Aþ. The impulsiveness of tibialis anterior EMG was
characteristic for other patients as well.
3.3. EMG features
The calculated EMG feature differences with respect to state S0


















































































































Fig. 3. EMG recordings from right TA of Patient 7 during seven different settings of the DBS treatment.
S.M. Rissanen et al. / Clinical Neurophysiology 126 (2015) 2290–2298 2295figure presents the feature difference in the specified setting state
for each subject. In each setting state, there are two dots per each
subject: one for the left side muscle and one for the right side mus-
cle of the subject. Because of severe adverse effects the scores
could not be evaluated for all 13 patients in all setting states.
Significant within-subject differences (paired samples t-test for
normally distributed variables and Wilcoxon signed rank test for
other variables, p < 0.05) were found in the following EMGparameter values. The sample kurtosis of BB EMG was significantly
different (higher in most of cases) with the states A;Aþ;Wþ and
OFF than with the state S0. Higher kurtosis indicates more impul-
sive (i.e. more PD-like) EMG signals (Rissanen et al., 2012). The cor-
relation dimension of BB EMG was significantly different (lower in
most of cases) with the states A;Aþ; F;Wþ and OFF than with
the state S0. Lower correlation dimension indicates more regular
(i.e. more PD-like) EMG signals (Rissanen et al., 2012). The






















































Fig. 4. Differences in the EMG parameter values with respect to state S0 for 13 PD patients (for each patient there is one right and one left side value) during each setting state
of DBS treatment.
2296 S.M. Rissanen et al. / Clinical Neurophysiology 126 (2015) 2290–2298recurrence rate of BB EMG was significantly different (higher in
most of cases) with the states A;Aþ; F; Fþ;Wþ and OFF than
with the state S0. Higher recurrence rate indicates higher number
of recurring EMG structures, which is typical for PD (Rissanen et al.,
2012). EMG–ACC coherence parameter was significantly different
(higher in most of cases) with the states A; F and OFF than with
the state S0. Higher coherence parameter is typical for PD
(Rissanen et al., 2012). In the EMG features of TA, there were no
significant differences with respect to state S0, which can be
observed as spreading of variable value differences in the Fig. 4.
The correlations between EMG feature values and clinical scores
(absolute values of rest tremor and rigidity) were quantified by
using the Spearman’s q-test. In the correlation analysis, all DBS
conditions were analyzed together. The number of values for eachEMG feature and clinical score was N = 160 (because all patients
could not be measured in all setting states). The correlation
between the arm tremor score and EMG variables was weak but
significant for kurtosis (R ¼ 0:241; p ¼ 0:002), for correlation
dimension (R ¼ 0:336; p ¼ 1:62 105) and for recurrence rate
(R ¼ 0:304; p ¼ 1:03 104). This implies that when the arm tre-
mor increases, the BB EMGs tend to get more impulsive and regular
and they tend to contain more recurrent structures. The correlation
between the arm rigidity score and EMG variables was weak but
significant for kurtosis (R ¼ 0:202; p ¼ 0:011) and for coherence
parameter (R ¼ 0:334; p ¼ 1:78 105). This implies that when
the arm rigidity increases, the BB EMGs tend to get more impulsive
and coherent with the involuntary arm movement. The increase in
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increase in the level of motor unit synchronization in muscles. It
has been suggested that during STN DBS and medication therapy,
the motor units are fired more independently than without
the therapy (Sturman et al., 2004). Between the leg tremor
score and EMG variables, the correlation was weak but significant
for kurtosis (R ¼ 0:368; p ¼ 2:69 106), for correlation
dimension (R ¼ 0:311; p ¼ 8:66 105) and for recurrence rate
(R ¼ 0:300; p ¼ 1:59 104). The correlation was not significant
between the leg rigidity score and any of the EMG variables.
There was a group of three patients (Patients 4, 9 and 11) that
did not have clinically observable tremor or rigidity with any of
the DBS settings. These patients had received DBS treatment main-
ly because of difficult on–off-fluctuation in symptoms. In this sub-
group of patients, there were differences between patients in the
BB EMG kurtosis and coherence response to different DBS settings.
The standard deviation of kurtosis between different DBS settings
was rk 6 0:21 for Patients 4 and 11 (right and left side arms), while
it was twice as high rk ¼ 0:42 for Patient 9 (right arm). The stan-
dard deviation of coherence variable was rc ¼ 1:20 for Patient 9
(left arm), while it was only rc 6 0:15 for Patients 4 and 11 (left
and right side arms).4. Discussion
Muscle activation of PD patients was studied here during differ-
ent settings of DBS treatment by using several EMG signal features.
The results showed that there are significant within-subject differ-
ences in the analyzed EMG signal features between different DBS
settings for BB but not for TA muscles. The inter-subject variability
of DBS effect was high in this study, which has been observed pre-
viously also by Kelly et al. (2010) and Rissanen et al. (2011).
DBS is effective in reducing motor symptoms in advanced PD
although the action mechanisms of the treatment method still stay
partly unclear. It is known that the efficacy of DBS depends on: the
optimal electrode placement, selecting of best electrode contacts,
and programming of stimulation pulse amplitude, frequency and
width. It is possible that surface EMG could help in quantifying effi-
cacy of DBS in PD and in adjusting the DBS-settings in some patients.
However, it is not known, how different DBS parameters affect the
muscle activation in PD. This study aimed to answer to that question.
There have been few previous studies that have analyzed differences
in the motor symptoms of PD between different settings of DBS by
using kinematic measurements (O’Suilleabhain et al., 2003; Mera
et al., 2011; Patel et al., 2009; Zwartjes et al., 2010). The number of
patients in those studies has been quite low (N 6 6) and surface
EMG has not been analyzed. Because the movements are caused
by muscle activation, it is possible that EMG could detect signs of
PD although the motor symptoms could not be detected using kine-
matic measurements or subjective clinical evaluation.
The response of DBS treatment is thought to be U-shaped. That
is, symptoms are usually improved when the electrical current or
voltage is increased. However, occasionally symptoms may get
worse if electrical current is further increased (Montgomery,
2010). The amplitude of electrical current is thought to be the most
significant factor in reducing parkinsonian symptoms. When the
stimulation amplitude is increased, the tremor and rigidity are
usually relieved (Volkmann et al., 2002). In this study, the mea-
surements were started with previously defined optimal para-
meter values. Stimulation amplitude was modified with small
steps (±0.3 V) responding to the typical adjustment session used
in PD patients with previously implanted DBS. The stimulation fre-
quency was kept inside the therapeutic frequency range (in most
patients 130 ± 30 Hz). It was noticed that the impulsiveness and
recurrent structure of EMG increased, and the complexity of EMGdecreased in most patients when the stimulation amplitude was
increased or decreased and the stimulation frequency was
decreased from previously defined optimal settings. It suggests
that the surface EMG features could point to the optimal settings
in most of patients, which could help the clinicians in arriving at
the optimal DBS settings more quantitatively.
In this study, different results were obtained for BB than for TA
muscles. In fact, it has been noticed recently that high-frequency
DBS may affect differently the upper than the lower extremity
muscle function. Systems Oscillations theory by Montgomery
(2010) provides one explanation for that. The theory suggests that
the basal ganglia-thalamo-cortical system consists of sets of nested
neural oscillators that each have a fundamental frequency.
Therapeutic DBS may resonate with specific oscillators leading to
improvement of physiological information processing. This theory
proposes that different motor functions have different carrier fre-
quencies that are determined by human anatomy. For example,
longer neural loops for lower limb motor control may operate at
lower frequencies than shorter neural loops for upper limb motor
control (Montgomery, 2010).
In this study, all patients were measured with medication on in
order to guarantee that patients can tolerate the study. The
medication on-state may have affected the results by decreasing
differences between different DBS setting -states in some patients.
It has been noticed earlier that both medication and DBS affect the
surface EMG signals in PD but neither one of them is able to nor-
malize the signals and muscle activation patterns (Sturman et al.,
2004, 2007; Vaillancourt et al., 2004, 2006; Robichaud et al.,
2002). It has been noticed that even with medication on, the DBS
affects the agonist EMG burst characteristics during movement
(Vaillancourt et al., 2004).
The patient group in this study was not restricted to such
patients that respond to different DBS settings within a short time.
Three patients did not respond to DBS with clinically observable
motor symptoms (tremor and rigidity) in this study. These patients
had received DBS treatment mainly because of difficult on–off-
fluctuation in symptoms. Two out of these patients showed smaller
changes in the surface EMG kurtosis and coherence of BB between
different DBS setting -states than one patient. One could think, if a
long-term EMG measurement could help in quantifying the muscle
activation of patients with difficult on–off-fluctuation of symp-
toms. However, some of the DBS setting -states cause such adverse
effects to the patients that the long-term measurement would not
be ethically reasonable.5. Conclusions
The results show that changes in the DBS-treatment parameters
cause changes to the surface EMG signal features of BB during iso-
metric muscle contraction. Although the correlation between the
EMG features and clinical scores was weak, the EMG changes
pointed to the optimal DBS settings in most of patients. It was
noticed that, if the patient does not have differences in the tremor
and rigidity score between different DBS settings, there can be dif-
ferences in the surface EMG signal features. This indicates a need
for further investigation on the DBS-induced muscle activation
changes of these patients. In the signal features of TA, significant
differences could not be observed in this study, which may
describe different mechanisms of DBS in affecting the upper and
lower limb muscle function. In general, surface EMG provides an
objective estimate of the muscle activation changes due to DBS
using quite simple measurement protocol. It can increase our
understanding on the action mechanisms of DBS in PD. In the
future, it may help in optimizing the DBS parameters in advanced
PD in combination with other quantitative methods.
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